Avacta Shares Rise As AVA3996 Selected for Pre-Clinical Development

Key points:

Avacta shares up 8%
AVA3996 selected for preclinical development
The pre|CISIONTM chemistry is used to alter chemotherapy drugs
Avacta Group PLC Stock Forecast

Shares of Avacta have risen just over 8% Tuesday after the company announced the next pre|CISIONTM drug candidate, AVA3996, has been selected for preclinical development.

The company’s pre|CISIONTM chemistry is used to alter chemotherapy drugs to make them inactive in the circulation until they enter the tumour micro-environment where they are then activated by an enzyme.

As a result, Avacta says the platform offers a way to reduce exposure to and improve the safety of cancer drugs by increasing the tolerability of chemotherapies.

X testing X

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Also Read: The Best Healthcare Stocks To Buy

Avacta explained that it reviewed efficacy studies and selected AVA3996 as a candidate for preclinical development. The aim for the company is a Clinical Trial Authorisation (CTA) and Investigational New Drug (IND) filing in the first half of 2023.

The first-in-human Phase 1 clinical trial is forecast to begin in the second half of 2023.

Dr Alastair Smith, CEO of Avacta Group, commented: “We are excited by the early pre-clinical data for AVA3996, the second of Avacta’s pre|CISIONTM pro-drugs following on from AVA6000. The pre|CISIONTM platform has the potential to generate a significant pipeline of safer, better tolerated chemotherapies to treat a wide range of cancers. It represents a major commercial opportunity and the principal value driver for the Group.”

Avacta shares are currently trading around the 79p area.